Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics (2020)
Attributed to:
China kadoorie biobank - University of Oxford
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.aay6570
PubMed Identifier: 32581134
Publication URI: http://europepmc.org/abstract/MED/32581134
Type: Journal Article/Review
Parent Publication: Science Translational Medicine
Issue: 549
ISSN: 1946-6234